CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: In conclusion, the present study indicated that imatinib significantly inhibited proliferation, induced apoptosis and reduced the tyrosine kinase activity of BCR-ABL in CD34+ cells from patients with CML in the megakaryocytic crisis phase.